Lucid Group

Bridging the Gap from Scientific Progress to System Readiness in Alzheimer’s Disease (AD)

Lucid Strategy Consulting

Header background logo

About This Perspective

 

The future of Alzheimer’s disease treatment depends on more than scientific innovation. Diagnostics, therapies and healthcare systems all have to evolve together to deliver meaningful patient impact at scale.

Download The Full Perspective

12
MEET THE AUTHORS:

Simon Bates - President, Consulting

Simon Bates is President of Lucid Strategy Consulting. He has extensive experience supporting pharma companies’ commercial strategies, including analysis of care ecosystems, clinical pathways and patient journeys. He has particular expertise in innovative market models and “beyond the pill” strategies such as companion diagnostics, population health, digital health and HCP/patient support solutions in neurodegenerative and other disease areas.

simon.bates@wearelucidgroup.com

 

MEET THE AUTHORS:

Callum Caldwell - VP, Consulting

Callum Caldwell is a Vice President at Lucid Strategy Consulting. His background includes brand, commercial and marketing director roles in major pharma. He specialises in defining commercialisation strategies for novel treatments requiring new go-to-market and service models that support technology-enabled and integrated care to transform the patient experience.

callum.caldwell@wearelucidgroup.com

Want to explore what these insights mean for your organization?

Book a Strategic Conversation

About Lucid Strategy Consulting

Turning complexity into measurable value across life sciences.

At Lucid Strategy Consulting, we combine business insight with deep life sciences expertise to deliver impact for our pharma, biotech and medtech clients. We help leaders unlock the full potential of their assets, create new value for their customers, drive better outcomes and experiences for patients, and transform internal operations to succeed in a changing external environment.